Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry chain, the market status of Liver Cancer (Bispecific Antibodies, Antibody Drug Conjugates), Respiratory Cancer (Bispecific Antibodies, Antibody Drug Conjugates), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Regionally, the report analyzes the B-Cell Maturation Antigen (BCMA) Targeted Therapies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Bispecific Antibodies, Antibody Drug Conjugates).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.
Regional Analysis: The report involves examining the B-Cell Maturation Antigen (BCMA) Targeted Therapies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to B-Cell Maturation Antigen (BCMA) Targeted Therapies:
Company Analysis: Report covers individual B-Cell Maturation Antigen (BCMA) Targeted Therapies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards B-Cell Maturation Antigen (BCMA) Targeted Therapies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Liver Cancer, Respiratory Cancer).
Technology Analysis: Report covers specific technologies relevant to B-Cell Maturation Antigen (BCMA) Targeted Therapies. It assesses the current state, advancements, and potential future developments in B-Cell Maturation Antigen (BCMA) Targeted Therapies areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
B-Cell Maturation Antigen (BCMA) Targeted Therapies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, with revenue, gross margin and global market share of B-Cell Maturation Antigen (BCMA) Targeted Therapies from 2019 to 2024.
Chapter 3, the B-Cell Maturation Antigen (BCMA) Targeted Therapies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and B-Cell Maturation Antigen (BCMA) Targeted Therapies market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Chapter 13, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies research findings and conclusion.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry chain, the market status of Liver Cancer (Bispecific Antibodies, Antibody Drug Conjugates), Respiratory Cancer (Bispecific Antibodies, Antibody Drug Conjugates), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Regionally, the report analyzes the B-Cell Maturation Antigen (BCMA) Targeted Therapies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the B-Cell Maturation Antigen (BCMA) Targeted Therapies industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Bispecific Antibodies, Antibody Drug Conjugates).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the B-Cell Maturation Antigen (BCMA) Targeted Therapies market.
Regional Analysis: The report involves examining the B-Cell Maturation Antigen (BCMA) Targeted Therapies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to B-Cell Maturation Antigen (BCMA) Targeted Therapies:
Company Analysis: Report covers individual B-Cell Maturation Antigen (BCMA) Targeted Therapies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards B-Cell Maturation Antigen (BCMA) Targeted Therapies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Liver Cancer, Respiratory Cancer).
Technology Analysis: Report covers specific technologies relevant to B-Cell Maturation Antigen (BCMA) Targeted Therapies. It assesses the current state, advancements, and potential future developments in B-Cell Maturation Antigen (BCMA) Targeted Therapies areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the B-Cell Maturation Antigen (BCMA) Targeted Therapies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
B-Cell Maturation Antigen (BCMA) Targeted Therapies market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Bispecific Antibodies
- Antibody Drug Conjugates
- Chimeric Antigen Receptor T-Cells
- Liver Cancer
- Respiratory Cancer
- Brain Cancer
- Others
- Transposagen Biopharmaceuticals
- Sutro Biopharma
- Malin Corporation
- Eureka Therapeutics
- firstVentury Equity
- Five Prime Therapeutics
- Credit Suisse Securities
- Dana-Farber Cancer Institute
- Deerfield Partners
- Onyx Pharmaceuticals
- Juno Therapeutics
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, with revenue, gross margin and global market share of B-Cell Maturation Antigen (BCMA) Targeted Therapies from 2019 to 2024.
Chapter 3, the B-Cell Maturation Antigen (BCMA) Targeted Therapies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and B-Cell Maturation Antigen (BCMA) Targeted Therapies market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of B-Cell Maturation Antigen (BCMA) Targeted Therapies.
Chapter 13, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of B-Cell Maturation Antigen (BCMA) Targeted Therapies
1.2 Market Estimation Caveats and Base Year
1.3 Classification of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Type
1.3.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type in 2023
1.3.3 Bispecific Antibodies
1.3.4 Antibody Drug Conjugates
1.3.5 Chimeric Antigen Receptor T-Cells
1.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Application
1.4.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Liver Cancer
1.4.3 Respiratory Cancer
1.4.4 Brain Cancer
1.4.5 Others
1.5 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size & Forecast
1.6 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast by Region
1.6.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region, (2019-2030)
1.6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.6 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Transposagen Biopharmaceuticals
2.1.1 Transposagen Biopharmaceuticals Details
2.1.2 Transposagen Biopharmaceuticals Major Business
2.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Transposagen Biopharmaceuticals Recent Developments and Future Plans
2.2 Sutro Biopharma
2.2.1 Sutro Biopharma Details
2.2.2 Sutro Biopharma Major Business
2.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.2.4 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sutro Biopharma Recent Developments and Future Plans
2.3 Malin Corporation
2.3.1 Malin Corporation Details
2.3.2 Malin Corporation Major Business
2.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.3.4 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Malin Corporation Recent Developments and Future Plans
2.4 Eureka Therapeutics
2.4.1 Eureka Therapeutics Details
2.4.2 Eureka Therapeutics Major Business
2.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.4.4 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Eureka Therapeutics Recent Developments and Future Plans
2.5 firstVentury Equity
2.5.1 firstVentury Equity Details
2.5.2 firstVentury Equity Major Business
2.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.5.4 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 firstVentury Equity Recent Developments and Future Plans
2.6 Five Prime Therapeutics
2.6.1 Five Prime Therapeutics Details
2.6.2 Five Prime Therapeutics Major Business
2.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.6.4 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Five Prime Therapeutics Recent Developments and Future Plans
2.7 Credit Suisse Securities
2.7.1 Credit Suisse Securities Details
2.7.2 Credit Suisse Securities Major Business
2.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.7.4 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Credit Suisse Securities Recent Developments and Future Plans
2.8 Dana-Farber Cancer Institute
2.8.1 Dana-Farber Cancer Institute Details
2.8.2 Dana-Farber Cancer Institute Major Business
2.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Dana-Farber Cancer Institute Recent Developments and Future Plans
2.9 Deerfield Partners
2.9.1 Deerfield Partners Details
2.9.2 Deerfield Partners Major Business
2.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.9.4 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Deerfield Partners Recent Developments and Future Plans
2.10 Onyx Pharmaceuticals
2.10.1 Onyx Pharmaceuticals Details
2.10.2 Onyx Pharmaceuticals Major Business
2.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Onyx Pharmaceuticals Recent Developments and Future Plans
2.11 Juno Therapeutics
2.11.1 Juno Therapeutics Details
2.11.2 Juno Therapeutics Major Business
2.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.11.4 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Juno Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Revenue
3.2.2 Top 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2023
3.2.3 Top 6 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2023
3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Overall Company Footprint Analysis
3.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Region Footprint
3.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Type Footprint
3.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value and Market Share by Type (2019-2024)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2024)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
6.3.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
6.3.2 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
6.3.3 Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
6.3.4 Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
7.3.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
7.3.2 Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.3 France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.4 United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.5 Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.6 Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region
8.3.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2030)
8.3.2 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.3 Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.4 South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.5 India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.7 Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
9.2 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
9.3 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
9.3.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
9.3.2 Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
9.3.3 Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
10.3.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
10.3.2 Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10.3.4 UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
11.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
11.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Chain
12.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Upstream Analysis
12.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Midstream Analysis
12.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of B-Cell Maturation Antigen (BCMA) Targeted Therapies
1.2 Market Estimation Caveats and Base Year
1.3 Classification of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Type
1.3.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type in 2023
1.3.3 Bispecific Antibodies
1.3.4 Antibody Drug Conjugates
1.3.5 Chimeric Antigen Receptor T-Cells
1.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Application
1.4.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Liver Cancer
1.4.3 Respiratory Cancer
1.4.4 Brain Cancer
1.4.5 Others
1.5 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size & Forecast
1.6 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast by Region
1.6.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region, (2019-2030)
1.6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.6 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 Transposagen Biopharmaceuticals
2.1.1 Transposagen Biopharmaceuticals Details
2.1.2 Transposagen Biopharmaceuticals Major Business
2.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Transposagen Biopharmaceuticals Recent Developments and Future Plans
2.2 Sutro Biopharma
2.2.1 Sutro Biopharma Details
2.2.2 Sutro Biopharma Major Business
2.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.2.4 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Sutro Biopharma Recent Developments and Future Plans
2.3 Malin Corporation
2.3.1 Malin Corporation Details
2.3.2 Malin Corporation Major Business
2.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.3.4 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Malin Corporation Recent Developments and Future Plans
2.4 Eureka Therapeutics
2.4.1 Eureka Therapeutics Details
2.4.2 Eureka Therapeutics Major Business
2.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.4.4 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Eureka Therapeutics Recent Developments and Future Plans
2.5 firstVentury Equity
2.5.1 firstVentury Equity Details
2.5.2 firstVentury Equity Major Business
2.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.5.4 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 firstVentury Equity Recent Developments and Future Plans
2.6 Five Prime Therapeutics
2.6.1 Five Prime Therapeutics Details
2.6.2 Five Prime Therapeutics Major Business
2.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.6.4 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Five Prime Therapeutics Recent Developments and Future Plans
2.7 Credit Suisse Securities
2.7.1 Credit Suisse Securities Details
2.7.2 Credit Suisse Securities Major Business
2.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.7.4 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Credit Suisse Securities Recent Developments and Future Plans
2.8 Dana-Farber Cancer Institute
2.8.1 Dana-Farber Cancer Institute Details
2.8.2 Dana-Farber Cancer Institute Major Business
2.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Dana-Farber Cancer Institute Recent Developments and Future Plans
2.9 Deerfield Partners
2.9.1 Deerfield Partners Details
2.9.2 Deerfield Partners Major Business
2.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.9.4 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Deerfield Partners Recent Developments and Future Plans
2.10 Onyx Pharmaceuticals
2.10.1 Onyx Pharmaceuticals Details
2.10.2 Onyx Pharmaceuticals Major Business
2.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Onyx Pharmaceuticals Recent Developments and Future Plans
2.11 Juno Therapeutics
2.11.1 Juno Therapeutics Details
2.11.2 Juno Therapeutics Major Business
2.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.11.4 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Juno Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Revenue
3.2.2 Top 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2023
3.2.3 Top 6 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2023
3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Overall Company Footprint Analysis
3.3.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Region Footprint
3.3.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Type Footprint
3.3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value and Market Share by Type (2019-2024)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2024)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
6.3.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
6.3.2 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
6.3.3 Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
6.3.4 Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
7.3.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
7.3.2 Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.3 France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.4 United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.5 Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
7.3.6 Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region
8.3.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2030)
8.3.2 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.3 Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.4 South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.5 India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
8.3.7 Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
9.2 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
9.3 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
9.3.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
9.3.2 Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
9.3.3 Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2030)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2030)
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
10.3.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2030)
10.3.2 Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
10.3.4 UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
11.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
11.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Chain
12.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Upstream Analysis
12.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Midstream Analysis
12.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Transposagen Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 6. Transposagen Biopharmaceuticals Major Business
Table 7. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 8. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Transposagen Biopharmaceuticals Recent Developments and Future Plans
Table 10. Sutro Biopharma Company Information, Head Office, and Major Competitors
Table 11. Sutro Biopharma Major Business
Table 12. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 13. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Sutro Biopharma Recent Developments and Future Plans
Table 15. Malin Corporation Company Information, Head Office, and Major Competitors
Table 16. Malin Corporation Major Business
Table 17. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 18. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Malin Corporation Recent Developments and Future Plans
Table 20. Eureka Therapeutics Company Information, Head Office, and Major Competitors
Table 21. Eureka Therapeutics Major Business
Table 22. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 23. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Eureka Therapeutics Recent Developments and Future Plans
Table 25. firstVentury Equity Company Information, Head Office, and Major Competitors
Table 26. firstVentury Equity Major Business
Table 27. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 28. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. firstVentury Equity Recent Developments and Future Plans
Table 30. Five Prime Therapeutics Company Information, Head Office, and Major Competitors
Table 31. Five Prime Therapeutics Major Business
Table 32. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 33. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Five Prime Therapeutics Recent Developments and Future Plans
Table 35. Credit Suisse Securities Company Information, Head Office, and Major Competitors
Table 36. Credit Suisse Securities Major Business
Table 37. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 38. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Credit Suisse Securities Recent Developments and Future Plans
Table 40. Dana-Farber Cancer Institute Company Information, Head Office, and Major Competitors
Table 41. Dana-Farber Cancer Institute Major Business
Table 42. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 43. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Dana-Farber Cancer Institute Recent Developments and Future Plans
Table 45. Deerfield Partners Company Information, Head Office, and Major Competitors
Table 46. Deerfield Partners Major Business
Table 47. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 48. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Deerfield Partners Recent Developments and Future Plans
Table 50. Onyx Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Onyx Pharmaceuticals Major Business
Table 52. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 53. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Onyx Pharmaceuticals Recent Developments and Future Plans
Table 55. Juno Therapeutics Company Information, Head Office, and Major Competitors
Table 56. Juno Therapeutics Major Business
Table 57. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 58. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Juno Therapeutics Recent Developments and Future Plans
Table 60. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) by Players (2019-2024)
Table 61. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players (2019-2024)
Table 62. Breakdown of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in B-Cell Maturation Antigen (BCMA) Targeted Therapies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key B-Cell Maturation Antigen (BCMA) Targeted Therapies Players
Table 65. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Type Footprint
Table 66. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Application Footprint
Table 67. B-Cell Maturation Antigen (BCMA) Targeted Therapies New Market Entrants and Barriers to Market Entry
Table 68. B-Cell Maturation Antigen (BCMA) Targeted Therapies Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Type (2019-2024)
Table 71. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Forecast by Type (2025-2030)
Table 72. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024)
Table 73. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Forecast by Application (2025-2030)
Table 74. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 104. B-Cell Maturation Antigen (BCMA) Targeted Therapies Raw Material
Table 105. Key Suppliers of B-Cell Maturation Antigen (BCMA) Targeted Therapies Raw Materials
Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2025-2030) & (USD Million)
Table 5. Transposagen Biopharmaceuticals Company Information, Head Office, and Major Competitors
Table 6. Transposagen Biopharmaceuticals Major Business
Table 7. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 8. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. Transposagen Biopharmaceuticals Recent Developments and Future Plans
Table 10. Sutro Biopharma Company Information, Head Office, and Major Competitors
Table 11. Sutro Biopharma Major Business
Table 12. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 13. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Sutro Biopharma Recent Developments and Future Plans
Table 15. Malin Corporation Company Information, Head Office, and Major Competitors
Table 16. Malin Corporation Major Business
Table 17. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 18. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. Malin Corporation Recent Developments and Future Plans
Table 20. Eureka Therapeutics Company Information, Head Office, and Major Competitors
Table 21. Eureka Therapeutics Major Business
Table 22. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 23. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Eureka Therapeutics Recent Developments and Future Plans
Table 25. firstVentury Equity Company Information, Head Office, and Major Competitors
Table 26. firstVentury Equity Major Business
Table 27. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 28. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. firstVentury Equity Recent Developments and Future Plans
Table 30. Five Prime Therapeutics Company Information, Head Office, and Major Competitors
Table 31. Five Prime Therapeutics Major Business
Table 32. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 33. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Five Prime Therapeutics Recent Developments and Future Plans
Table 35. Credit Suisse Securities Company Information, Head Office, and Major Competitors
Table 36. Credit Suisse Securities Major Business
Table 37. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 38. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Credit Suisse Securities Recent Developments and Future Plans
Table 40. Dana-Farber Cancer Institute Company Information, Head Office, and Major Competitors
Table 41. Dana-Farber Cancer Institute Major Business
Table 42. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 43. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Dana-Farber Cancer Institute Recent Developments and Future Plans
Table 45. Deerfield Partners Company Information, Head Office, and Major Competitors
Table 46. Deerfield Partners Major Business
Table 47. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 48. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Deerfield Partners Recent Developments and Future Plans
Table 50. Onyx Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 51. Onyx Pharmaceuticals Major Business
Table 52. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 53. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Onyx Pharmaceuticals Recent Developments and Future Plans
Table 55. Juno Therapeutics Company Information, Head Office, and Major Competitors
Table 56. Juno Therapeutics Major Business
Table 57. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 58. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. Juno Therapeutics Recent Developments and Future Plans
Table 60. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) by Players (2019-2024)
Table 61. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players (2019-2024)
Table 62. Breakdown of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in B-Cell Maturation Antigen (BCMA) Targeted Therapies, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key B-Cell Maturation Antigen (BCMA) Targeted Therapies Players
Table 65. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Type Footprint
Table 66. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market: Company Product Application Footprint
Table 67. B-Cell Maturation Antigen (BCMA) Targeted Therapies New Market Entrants and Barriers to Market Entry
Table 68. B-Cell Maturation Antigen (BCMA) Targeted Therapies Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Type (2019-2024)
Table 71. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Forecast by Type (2025-2030)
Table 72. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024)
Table 73. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Forecast by Application (2025-2030)
Table 74. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Country (2025-2030) & (USD Million)
Table 104. B-Cell Maturation Antigen (BCMA) Targeted Therapies Raw Material
Table 105. Key Suppliers of B-Cell Maturation Antigen (BCMA) Targeted Therapies Raw Materials
LIST OF FIGURES
Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Picture
Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type in 2023
Figure 4. Bispecific Antibodies
Figure 5. Antibody Drug Conjugates
Figure 6. Chimeric Antigen Receptor T-Cells
Figure 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 8. B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application in 2023
Figure 9. Liver Cancer Picture
Figure 10. Respiratory Cancer Picture
Figure 11. Brain Cancer Picture
Figure 12. Others Picture
Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region (2019-2030)
Figure 17. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region in 2023
Figure 18. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 21. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 23. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players in 2023
Figure 24. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share in 2023
Figure 26. Global Top 6 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share in 2023
Figure 27. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Type (2019-2024)
Figure 28. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Type (2025-2030)
Figure 29. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Application (2019-2024)
Figure 30. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Application (2025-2030)
Figure 31. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 32. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 33. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 34. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 41. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region (2019-2030)
Figure 48. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 51. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 54. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 55. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 56. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 65. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
Figure 66. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
Figure 67. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies in 2023
Figure 70. Manufacturing Process Analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies
Figure 71. B-Cell Maturation Antigen (BCMA) Targeted Therapies Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Picture
Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type in 2023
Figure 4. Bispecific Antibodies
Figure 5. Antibody Drug Conjugates
Figure 6. Chimeric Antigen Receptor T-Cells
Figure 7. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 8. B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application in 2023
Figure 9. Liver Cancer Picture
Figure 10. Respiratory Cancer Picture
Figure 11. Brain Cancer Picture
Figure 12. Others Picture
Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 16. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region (2019-2030)
Figure 17. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region in 2023
Figure 18. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 19. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 20. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 21. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 22. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 23. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players in 2023
Figure 24. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 25. Global Top 3 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share in 2023
Figure 26. Global Top 6 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share in 2023
Figure 27. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Type (2019-2024)
Figure 28. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Type (2025-2030)
Figure 29. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Share by Application (2019-2024)
Figure 30. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Application (2025-2030)
Figure 31. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 32. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 33. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 34. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 35. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 36. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 37. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 38. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 39. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 40. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 41. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 42. United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 43. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 44. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 45. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 46. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 47. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Region (2019-2030)
Figure 48. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 49. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 50. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 51. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 52. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 53. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 54. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 55. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 56. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 57. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 58. Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 59. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Type (2019-2030)
Figure 60. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Application (2019-2030)
Figure 61. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value Market Share by Country (2019-2030)
Figure 62. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 63. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 64. UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Consumption Value (2019-2030) & (USD Million)
Figure 65. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
Figure 66. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
Figure 67. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
Figure 68. Porters Five Forces Analysis
Figure 69. Manufacturing Cost Structure Analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies in 2023
Figure 70. Manufacturing Process Analysis of B-Cell Maturation Antigen (BCMA) Targeted Therapies
Figure 71. B-Cell Maturation Antigen (BCMA) Targeted Therapies Industrial Chain
Figure 72. Methodology
Figure 73. Research Process and Data Source
